President Joe Biden today renewed his goal of 100 million vaccines given in his first 100 days in office to 200 million vaccines.
"We met our first goal in the 58th day," said Biden. "I know it's interesting, it's doubled our original goal, but no other country in the world is closer."
Today Biden’s day is 65 instead; The 100 will be on April 30.
Vaccination rates are skyrocketing and are now estimated at 2.5 million guns per day, with many provinces announcing plans to open vaccines for all adults in the coming weeks. Alaska, Mississippi, West Virginia, and Georgia will allow all adults or citizens older than 16 to have access to immunizations starting today.
Next week, according to CNN, Oklahoma, Texas, Ohio, North Dakota, Louisiana, and Indiana will join in opening the goal for all adults.
The Center for Disease Control and Prevention (CDC) COVID Data Tracker shows that 169,223,125 vaccine doses of COVID-19 have been distributed in the US, and 133,305,295 have been provided, and 47,419,833 Americans have been completely vaccinated.
Half of the K-8 schools are open; a lot of money in vulnerable communities
Biden said his superiors were on the verge of meeting one of his goals in the first 100 days of his administration: opening all K-8 schools for public education. Biden said about 50% of K-8 schools across the country are open for 5 days a week for students, and he is confident that the other half will get there in the coming weeks.
The president also announced a $ 10 billion fundraiser to increase access to COVID-19 vaccines in the worst-hit U.S. communities.
In a separate financial statement today, the CDC has announced that it will provide $ 332 million to public health workers with the protection and control of COVID-19 in vulnerable communities.
"These resources will enhance the incredible work of our country's public health workers in the areas most affected by COVID-19," CDC Director Rochelle Walensky, MD, MPH said in a statement. "Community health workers are trusted ambassadors to communities, and they contribute to linking high-risk and high-risk people to care for and in need of services, and to address the challenges of local community health."
AstraZeneca issues a basic analysis, validating the findings
AstraZeneca said baseline analysis of phase 3 data from the US trial of their prescription drug showed 100% effectiveness in preventing death and hospitalization, 85% effective against COVID-19 symptoms in participants 65 years of age and older, and and 76% effective in symptom protection COVID-19.
An analysis was made earlier this week when the data monitoring and security board told the National Institutes of Health that it was concerned that AstraZeneca was using outdated data to show the effectiveness of its two-dose vaccine, which is already widely used in Europe. Those previous results showed that the vaccine was 79% effective in preventing symptomatic COVID-19.
"These results have been presented by the Independent Data Security Monitoring Board. The basic analysis is pre-specified in the process and will form the basis for the official submission of emergency authorization to the US Food and Drug Administration in the coming weeks," AstraZeneca said in a press release.
The country is reaching 30 million cases
Yesterday, the United States reported 86,903 new cases of COVID-19 and 1,454 deaths, according to Johns Hopkins COVID-19.
In total, the country has confirmed 30,057,034 cases, with 545,895 deaths.